Literature DB >> 23607636

Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients.

Francesco Izzo1, Mauro Piccirillo, Vittorio Albino, Raffaele Palaia, Andrea Belli, Vincenza Granata, Sergio Setola, Roberta Fusco, Antonella Petrillo, Raffaele Orlando, Grazia Tosone, Fabrizio Scordino, Steven A Curley.   

Abstract

OBJECTIVES: Historically, only 10% of patients with hepatocellular carcinoma (HCC) are diagnosed with early-stage, potentially curable disease. In this study, chronic hepatitis virus-infected patients were prospectively screened to determine: (i) the proportion of patients diagnosed with potentially curable HCC, and (ii) survival following curative therapy.
METHODS: The study included 8900 chronic hepatitis virus-infected patients enrolled in a prospective screening programme, of whom 1335 (15.0%) were infected with hepatitis B virus (HBV), 7120 (80.0%) with hepatitis C virus (HCV), and 445 (5.0%) with both HBV and HCV. Screening was conducted every 6 months and included serum alpha-fetoprotein (AFP) measurement and ultrasonography. Curative treatments included liver transplantation, resection, radiofrequency ablation and/or ethanol injection.
RESULTS: Hepatocellular carcinoma was diagnosed in 765 (8.6%) patients. Of 1602 patients with cirrhosis, 758 (47.3%) developed HCC. Curative treatment was possible in 523 (68.4%) of the 765 HCC patients. Two- and 5-year rates of overall survival in the curative treatment group were 65% and 28%, respectively, compared with 10% and 0% in the advanced disease group (P < 0.001).
CONCLUSIONS: Prospective screening of patients at high risk for the development of HCC increases the proportion of patients diagnosed with potentially curable disease. This may result in an increase in the number of longterm survivors. Screening strategies should focus on patients with chronic HBV or HCV infection who have progressed to cirrhosis because more than 40% of these patients will develop HCC.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607636      PMCID: PMC3843617          DOI: 10.1111/hpb.12080

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  36 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  Eur J Cancer       Date:  2012-03       Impact factor: 9.162

2.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

4.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Authors:  Adrian M Di Bisceglie; Richard K Sterling; Raymond T Chung; James E Everhart; Jules L Dienstag; Herbert L Bonkovsky; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; William M Lee; Timothy R Morgan; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

5.  Can hepatocellular cancer screening increase the proportion of long-term survivors?

Authors:  Christopher J Gannon; Francesco Izzo; Thomas A Aloia; Sandro Pignata; Guglielmo Nasti; Paolo Vallone; Raffaele Orlando; Fabrizio Scordino; Steven A Curley
Journal:  Hepatogastroenterology       Date:  2009 Jul-Aug

6.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

7.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

8.  Surgery for hepatocellular carcinoma: does it improve survival?

Authors:  Jerome H Liu; Pauline W Chen; Steven M Asch; Ronald W Busuttil; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

9.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

10.  Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival.

Authors:  Chi-Sin Changchien; Chao-Long Chen; Yi-Hao Yen; Jing-Houng Wang; Tsung-Hui Hu; Chuan-Mo Lee; Chih-Chi Wang; Yu-Fan Cheng; Yu-Jie Huang; Chih-Yun Lin; Sheng-Nan Lu
Journal:  J Gastroenterol       Date:  2008-02-29       Impact factor: 7.527

View more
  10 in total

Review 1.  Complications Risk Assessment and Imaging Findings of Thermal Ablation Treatment in Liver Cancers: What the Radiologist Should Expect.

Authors:  Vincenza Granata; Roberta Fusco; Federica De Muzio; Carmen Cutolo; Sergio Venanzio Setola; Igino Simonetti; Federica Dell'Aversana; Francesca Grassi; Federico Bruno; Andrea Belli; Renato Patrone; Vincenzo Pilone; Antonella Petrillo; Francesco Izzo
Journal:  J Clin Med       Date:  2022-05-13       Impact factor: 4.964

2.  Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.

Authors:  Hyun A Kim; Kyung Ah Kim; Joon-Il Choi; Jeong Min Lee; Chang Hee Lee; Tae Wook Kang; Young-Mi Ku; Su Lim Lee; Yang Shin Park; Jeong Hee Yoon; Seong Hyun Kim; Moon Hyung Choi
Journal:  BMC Cancer       Date:  2017-12-21       Impact factor: 4.430

3.  A Seven-Year Retrospective Study on the Surveillance of Hepatitis B in Laos.

Authors:  Phimpha Paboriboune; Thomas Vial; François Chassagne; Philavanh Sitbounlang; Sengaloun Soundala; Stéphane Bertani; Davone Sengmanothong; Francois-Xavier Babin; Nicolas Steenkeste; Paul Dény; Pascal Pineau; Eric Deharo
Journal:  Int J Hepatol       Date:  2018-04-01

4.  Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B.

Authors:  Christina Wang; Vincent Chen; Vinh Vu; An Le; Linda Nguyen; Changqing Zhao; Carrie R Wong; Nghia Nguyen; Jiayi Li; Jian Zhang; Huy Trinh; Mindie H Nguyen
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

5.  Nutritional risk screening 2002 and ASA score predict mortality after elective liver resection for malignancy.

Authors:  Thomas Zacharias; Nelio Ferreira
Journal:  Arch Med Sci       Date:  2017-02-15       Impact factor: 3.318

Review 6.  Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.

Authors:  Carmen Cutolo; Federica Dell'Aversana; Roberta Fusco; Giulia Grazzini; Giuditta Chiti; Igino Simonetti; Federico Bruno; Pierpaolo Palumbo; Luca Pierpaoli; Tommaso Valeri; Francesco Izzo; Andrea Giovagnoni; Roberto Grassi; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-04-02

Review 7.  Imaging Features of Post Main Hepatectomy Complications: The Radiologist Challenging.

Authors:  Carmen Cutolo; Federica De Muzio; Roberta Fusco; Igino Simonetti; Andrea Belli; Renato Patrone; Francesca Grassi; Federica Dell'Aversana; Vincenzo Pilone; Antonella Petrillo; Francesco Izzo; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-05-26

Review 8.  A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.

Authors:  Federica De Muzio; Francesca Grassi; Federica Dell'Aversana; Roberta Fusco; Ginevra Danti; Federica Flammia; Giuditta Chiti; Tommaso Valeri; Andrea Agostini; Pierpaolo Palumbo; Federico Bruno; Carmen Cutolo; Roberta Grassi; Igino Simonetti; Andrea Giovagnoni; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-07-07

9.  Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors.

Authors:  Ahmed Abdelmabood Zeeneldin; Salem Eid Salem; Amira Diaa Darwish; Mosaad Mahmoud El-Gammal; Marwa Mahmoud Hussein; Mohamed Saadeldin
Journal:  J Hepatocell Carcinoma       Date:  2015-01-30

10.  A Primary Screening Method for Liver Cancer in Chronic Hepatitis B Carriers: A Prospective Community-Based Cohort Study.

Authors:  Maomao Cao; He Li; Dianqin Sun; Siyi He; Changfa Xia; Lin Lei; Ji Peng; Wanqing Chen
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.